T. Rowe Price Associates
FDMT icon

T. Rowe Price Associates’s 4D Molecular Therapeutics FDMT Stock Holding History

T. Rowe Price Associates’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$730K Buy
54,869
+12,422
+29% +$121K ﹤0.01% 2452
2026
Q1 		$396K Buy
42,447
+3,700
+10% +$32.2K ﹤0.01% 2547
2025
Q4 		$291K Sell
38,747
-6,281
-14% -$63.7K ﹤0.01% 2659
2025
Q3 		$392K Buy
45,028
+9,700
+27% +$58K ﹤0.01% 2469
2025
Q2 		$132K Buy
35,328
+8,800
+33% +$30.9K ﹤0.01% 2836
2025
Q1 		$86K Sell
26,528
-18
-0.1% -$85 ﹤0.01% 2855
2024
Q4 		$148K Sell
26,546
-3,989
-13% -$31.3K ﹤0.01% 2770
2024
Q3 		$331K Buy
30,535
+491
+2% +$8.15K ﹤0.01% 2431
2024
Q2 		$631K Buy
30,044
+6,092
+25% +$153K ﹤0.01% 2097
2024
Q1 		$764K Buy
23,952
+1,356
+6% +$34.6K ﹤0.01% 2025
2023
Q4 		$458K Buy
22,596
+1,106
+5% +$14.6K ﹤0.01% 2214
2023
Q3 		$274K Buy
21,490
+2,570
+14% +$43K ﹤0.01% 2370
2023
Q2 		$342K Buy
18,920
+539
+3% +$9.92K ﹤0.01% 2307
2023
Q1 		$316K Buy
18,381
+1,002
+6% +$19.5K ﹤0.01% 2322
2022
Q4 		$386K Sell
17,379
-729
-4% -$11.3K ﹤0.01% 2267
2022
Q3 		$146K Buy
18,108
+2,318
+15% +$21K ﹤0.01% 2634
2022
Q2 		$110K Buy
15,790
+4,415
+39% +$42.9K ﹤0.01% 2738
2022
Q1 		$172K Buy
11,375
+700
+7% +$11K ﹤0.01% 2745
2021
Q4 		$234K Buy
+10,675
New +$262K ﹤0.01% 2700
2021
Q2 		– Sell
-279,746
Closed -$12.1M – 2932
2021
Q1 		$12.1M Sell
279,746
-63,932
-19% -$2.83M ﹤0.01% 1364
2020
Q4 		$14.2M Buy
+343,678
New +$14.2M ﹤0.01% 1297

Other funds holding FDMT

JT
Jupiter Topco New York $245B AUM
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM

T. Rowe Price Associates's FDMT Position: Q2 2026 in Review

T. Rowe Price Associates increased its 4D Molecular Therapeutics (FDMT) stake by 29% in Q2 2026, buying an estimated $121K and bringing the position to 54,869 shares worth $730K. The position accounts for ﹤0.01% of the portfolio, ranked #2452.

T. Rowe Price Associates first reported a position in FDMT in Q4 2020 and has held it in 21 quarters since. The position peaked at $14.2M in Q4 2020. 158 funds tracked by Wall St. Rank hold FDMT as of Q2 2026.

  • T. Rowe Price Associates held 54,869 shares of 4D Molecular Therapeutics worth $730K as of Q2 2026.
  • T. Rowe Price Associates bought 12,422 4D Molecular Therapeutics shares in Q2 2026, an estimated $121K.
  • 4D Molecular Therapeutics made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #2452 holding.
  • T. Rowe Price Associates first reported a position in 4D Molecular Therapeutics in Q4 2020 and has held it in 21 quarters since.
  • T. Rowe Price Associates's 4D Molecular Therapeutics position peaked at $14.2M in Q4 2020.
  • 158 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.